Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 15/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251951 | 0.92 | TNK2 (0.49) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL26820365 | 0.92 | TNK2 (0.49) | TNK2FGFR2IGF1RFGFR1 | |
| Hydrochloric Acid SCHEMBL26661660 | 0.91 | TNK2 (0.48) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL398874 | 0.87 | FGFR2 (0.57) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL4316054 | 0.85 | TNK2 (0.48) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL29614516 | 0.85 | TNK2 (0.45) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL16748847 | 0.84 | TNK2 (0.56) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL402054 | 0.83 | TNK2 (0.59) | TNK2FGFR2IGF1R | |
| SCHEMBL401909 | 0.83 | TNK2 (0.59) | TNK2FGFR2IGF1R | |
| SCHEMBL594940 | 0.80 | TNK2 (0.59) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2385053-A2 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2325186-A2 | Fused Bicyclic mTor Inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | TNK2 2837/4885FGFR2 306/4885IGF1R 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.